Cancer treatment and the KIR–HLA system

an overview

Patrizia Leone, Valli De Re, Angelo Vacca, Franco Dammacco, Vito Racanelli

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Accumulating evidence indicates that the success of cancer therapy depends not only on a combination of adequate procedures (surgery, chemotherapy and radiotherapy) that aim to eliminate all tumor cells, but also on the functional state of the host immune system. HLA and KIR molecules, in particular, are critical to the interactions between tumor cells and both innate and adaptive immune cells such as NK cells and T cells. Different KIR–HLA gene combinations as well as different HLA expression levels on tumor cells associate with variable tumor prognosis and response to treatment. On the other hand, different therapies have different effects on HLA molecules and immune cell functions regulated by these molecules. Here, we provide an overview of the KIR–HLA system, a description of its alterations with clinical relevance in diverse tumor types, and an analysis of the consequences that conventional cancer therapies may have on it. We also discuss how this knowledge can be exploited to identify potential immunological biomarkers that can help to select patients for tailored therapy.

Original languageEnglish
Pages (from-to)419-429
Number of pages11
JournalClinical and Experimental Medicine
Volume17
Issue number4
DOIs
Publication statusPublished - Nov 1 2017

Fingerprint

Oncology
Tumors
Cells
Neoplasms
Molecules
Therapeutics
Chemotherapy
T-cells
Immune system
Radiotherapy
Biomarkers
Surgery
Genes
Natural Killer Cells
Immune System
T-Lymphocytes
Drug Therapy

Keywords

  • Cancer treatment
  • HLA
  • KIR
  • NK cells
  • T cells
  • Tumor immune evasion

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Cancer treatment and the KIR–HLA system : an overview. / Leone, Patrizia; De Re, Valli; Vacca, Angelo; Dammacco, Franco; Racanelli, Vito.

In: Clinical and Experimental Medicine, Vol. 17, No. 4, 01.11.2017, p. 419-429.

Research output: Contribution to journalReview article

Leone, Patrizia ; De Re, Valli ; Vacca, Angelo ; Dammacco, Franco ; Racanelli, Vito. / Cancer treatment and the KIR–HLA system : an overview. In: Clinical and Experimental Medicine. 2017 ; Vol. 17, No. 4. pp. 419-429.
@article{7c7022e035094a5696314c4532ac1285,
title = "Cancer treatment and the KIR–HLA system: an overview",
abstract = "Accumulating evidence indicates that the success of cancer therapy depends not only on a combination of adequate procedures (surgery, chemotherapy and radiotherapy) that aim to eliminate all tumor cells, but also on the functional state of the host immune system. HLA and KIR molecules, in particular, are critical to the interactions between tumor cells and both innate and adaptive immune cells such as NK cells and T cells. Different KIR–HLA gene combinations as well as different HLA expression levels on tumor cells associate with variable tumor prognosis and response to treatment. On the other hand, different therapies have different effects on HLA molecules and immune cell functions regulated by these molecules. Here, we provide an overview of the KIR–HLA system, a description of its alterations with clinical relevance in diverse tumor types, and an analysis of the consequences that conventional cancer therapies may have on it. We also discuss how this knowledge can be exploited to identify potential immunological biomarkers that can help to select patients for tailored therapy.",
keywords = "Cancer treatment, HLA, KIR, NK cells, T cells, Tumor immune evasion",
author = "Patrizia Leone and {De Re}, Valli and Angelo Vacca and Franco Dammacco and Vito Racanelli",
year = "2017",
month = "11",
day = "1",
doi = "10.1007/s10238-017-0455-4",
language = "English",
volume = "17",
pages = "419--429",
journal = "Zeitschrift für Die Gesamte Experimentelle Medizin",
issn = "1591-8890",
publisher = "Springer-Verlag Italia",
number = "4",

}

TY - JOUR

T1 - Cancer treatment and the KIR–HLA system

T2 - an overview

AU - Leone, Patrizia

AU - De Re, Valli

AU - Vacca, Angelo

AU - Dammacco, Franco

AU - Racanelli, Vito

PY - 2017/11/1

Y1 - 2017/11/1

N2 - Accumulating evidence indicates that the success of cancer therapy depends not only on a combination of adequate procedures (surgery, chemotherapy and radiotherapy) that aim to eliminate all tumor cells, but also on the functional state of the host immune system. HLA and KIR molecules, in particular, are critical to the interactions between tumor cells and both innate and adaptive immune cells such as NK cells and T cells. Different KIR–HLA gene combinations as well as different HLA expression levels on tumor cells associate with variable tumor prognosis and response to treatment. On the other hand, different therapies have different effects on HLA molecules and immune cell functions regulated by these molecules. Here, we provide an overview of the KIR–HLA system, a description of its alterations with clinical relevance in diverse tumor types, and an analysis of the consequences that conventional cancer therapies may have on it. We also discuss how this knowledge can be exploited to identify potential immunological biomarkers that can help to select patients for tailored therapy.

AB - Accumulating evidence indicates that the success of cancer therapy depends not only on a combination of adequate procedures (surgery, chemotherapy and radiotherapy) that aim to eliminate all tumor cells, but also on the functional state of the host immune system. HLA and KIR molecules, in particular, are critical to the interactions between tumor cells and both innate and adaptive immune cells such as NK cells and T cells. Different KIR–HLA gene combinations as well as different HLA expression levels on tumor cells associate with variable tumor prognosis and response to treatment. On the other hand, different therapies have different effects on HLA molecules and immune cell functions regulated by these molecules. Here, we provide an overview of the KIR–HLA system, a description of its alterations with clinical relevance in diverse tumor types, and an analysis of the consequences that conventional cancer therapies may have on it. We also discuss how this knowledge can be exploited to identify potential immunological biomarkers that can help to select patients for tailored therapy.

KW - Cancer treatment

KW - HLA

KW - KIR

KW - NK cells

KW - T cells

KW - Tumor immune evasion

UR - http://www.scopus.com/inward/record.url?scp=85012159723&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85012159723&partnerID=8YFLogxK

U2 - 10.1007/s10238-017-0455-4

DO - 10.1007/s10238-017-0455-4

M3 - Review article

VL - 17

SP - 419

EP - 429

JO - Zeitschrift für Die Gesamte Experimentelle Medizin

JF - Zeitschrift für Die Gesamte Experimentelle Medizin

SN - 1591-8890

IS - 4

ER -